Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Feb 11, 2019 12:17pm
106 Views
Post# 29347418

RE:RE:RE:RE:RE:Sales Revenue (4147 TMB) January 2019

RE:RE:RE:RE:RE:Sales Revenue (4147 TMB) January 2019
SPCEO1 wrote:
palinc2000 wrote:
SPCEO1 wrote: The Bloomberg data is the best source of data now and it is showing improvement, with last week's number being the highest yet by a nice margin. The Taimed sales number is impacted by inventory changes at TH.
Dwizell wrote:
Garp1 wrote:
38,939


This is very bad as we don’t have the J code excuses for this 4 th near flat month in a row ...

 


Do you know for a fact that inventories held at TH  have decreased ?
Why would they decrease inventories when sales are supposedly increasing?
 


No, but it has to be the case since Trogarzo sales are rising at the TH level (according to Bloomberg, which has its problems but is generally accurate). Since TH can't sell what it does not have and its sales of Trogarzo are rising, that means they have to be working down invetories of Trogarzo if Taimed's Trogarzo sales to TH are flattish.  


The thing is if sales were improving in a substantial way then you would expect BOTH numbers to increase. Especially given that early in the process thera said they didnt actually hold much stock and the increases in taimed sales in the few months were they increased (i think the best month was 510000) were quite limited. There really isnt a great deal of spare inventory in the system. As others have said there is a limited life to this explanation and it seems we've come to the end of it.

SPCEO any chance you could give us the last weeks actual bloomberg sales. Is it vials sold? The actual number of vials? Or maybe 4 week moving average?

Bullboard Posts